Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Phase
Not applicable
Started
2025-05-12
Last updated
2025-05-16
Condition(s) studied
Carotid Artery Stenosis
Investigational drug(s) / intervention(s)
Neurovascular Intravascular Shockwave Catheter
Neurovascular Intravascular Shockwave Catheter: Device:
Neurovascular Intravascular Shockwave Catheter (single-use, rapid-exchange balloon catheter with integrated shockwave emitters).
Intravascular Shockwave Therapy Device (IVL-HVG-N01, generates localized shockwaves to fracture calcifications).
Procedure:
Patients undergo standard CAS preparation with guidewire placement and cerebral protection.
If conventional balloon angioplasty fails (residual stenosis \>70%), the IVL catheter is advanced to the target lesion.
Shockwave therapy is applied at 6 atm, followed by low-pressure balloon dilation (8 atm) if needed.
Subsequent stent deployment is performed per standard practice.
Study summary
* Clinical Trial Summary
* Trial Title:\*\* CREATE Trial: Safety and Efficacy of IVL for Carotid Calcified Lesions
* Sponsor:\*\* Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
* Clinical Trial Leader:\*\* Beijing Anzhen Hospital
* Coordinating Investigator:\*\* Prof. Huo Xiaochuan
* Study Purpose This trial assesses a new device-a single-use neurovascular intravascular shockwave catheter and therapy device-for treating calcified blockages in the carotid artery. It uses sound waves to break up calcium deposits, facilitating stent placement and blood flow restoration.
* Eligibility
* Adults aged 18-80 with severe carotid artery narrowing (≥50% symptomatic or ≥70% asymptomatic) due to calcium buildup.
* Patients who failed standard balloon dilation.
* Exclusions include pregnancy, recent strokes/heart attacks, uncontrolled hypertension, or other high-risk conditions.
* Study Design
1. \*\*Pre-treatment:\*\* Imaging (CT angiography, ultrasound) to confirm eligibility.
2. \*\*Procedure:\*\* Shockwave catheter breaks up calcium, followed by stent placement.
3. \*\*Follow-up:\*\* Assessments at 7 days (or discharge) and 1 month post-procedure.
* Benefits and Risks
* \*\*Benefits:\*\* Improved stent placement success, reduced risk of complications, minimally invasive with shorter recovery time.
* \*\*Risks:\*\* Bleeding, infection, vessel damage, stroke, heart attack, device malfunction. Risks are closely monitored with emergency protocols.
* Patient Protections
* Ethics committee approval and strict safety guidelines.
* Voluntary participation with the option to withdraw anytime.
* Free treatment and compensation for trial-related injuries.
* For Healthcare Providers
* \*\*Innovation:\*\* Adapts coronary lithotripsy technology for carotid use.
* \*\*Evidence:\*\* Supported by preclinical data and a pilot study (100% success rate in 5 patients).
* \*\*Endpoints:\*\* Primary: Stent success (residual stenosis \<30%) and 30-day major adverse events. Secondary: Device success rate, repeat procedures, long-term outcomes.
* Contact Information
Inclusion Criteria:
1. Age 18-80 years (inclusive), gender unrestricted.
2. Extracranial carotid artery: Preoperative CT angiography (CTA) confirms symptomatic carotid stenosis ≥50% or asymptomatic carotid stenosis ≥70% with calcification (CTA measurement: calcification \> 50% of circumference).
Note: (Extracranial carotid artery: Internal carotid artery or carotid bifurcation; Symptomatic refers to having had a non-disabling ischemic stroke or TIA within 6 months.)
3. Intraoperative digital subtraction angiography (DSA) confirms carotid stenosis ≥50% (by NASCET criteria) or asymptomatic carotid stenosis ≥70% (by NASCET criteria).
4. Participants with a pre-enrollment modified Rankin Scale (mRS) score ≤2.
5. Participants planned for carotid artery stenting (CAS) who have failed conventional balloon dilation.
6. Patients or their legal guardians understand the purpose of the trial, provide informed consent, and agree to follow-up.
Exclusion Criteria:
1. Target lesion caused by non-atherosclerotic disease.
2. Participants with complete occlusion of the target lesion or contralateral carotid artery.
3. Participants with severe disability due to cerebral infarction.
4. Participants with large acute or subacute thrombi near the target lesion, or with arteriovenous malformations or aneurysms.
5. Participants with tortuous target lesion vessels that prevent stent placement.
6. Participants with symptomatic severe stenosis in other cerebral vessels.
7. Participants requiring concurrent or additional surgical interventions during the trial period.
8. Participants with tandem severe stenosis or occlusion in vessels proximal or distal to the target lesion.
9. Participants who have had a myocardial infarction or large cerebral infarction within 2 weeks prior to screening.
10. Participants who have had intracranial hemorrhage within 3 months prior to screening.
11. Participants with vulnerable or high-risk plaques (unstable, prone to rupture, and thrombosis leading to acute cardiovascular events or death) as judged by carotid ultrasound.
12. Participants with uncontrolled hypertension (systolic blood pressure persistently ≥180 mmHg or diastolic blood pressure persistently ≥110 mmHg).
13. Participants with known platelet count \< 90×10\^9/L, severe liver impairment (transaminases \> 3 times the upper limit of normal), severe renal impairment (serum creatinine \> 2.5 mg/dL \[221 µmol/L\]), or New York Heart Association Class IV heart failure.
14. Participants with coagulopathy (INR ≥2.0) or contraindications to heparin or antiplatelet agents.
15. Participants with active infections.
16. Participants unable to use cerebral protection devices.
17. Participants allergic to components of the investigational device or contrast agents (excluding rash).
18. Participants with life expectancy less than 1 year.
19. Pregnant or breastfeeding women.
20. Participants currently enrolled in another drug or medical device clinical trial (before reaching the primary endpoint).
21. Other situations where the investigator deems the participant unsuitable for the trial.
Primary outcome measure(s)
Procedural Success Rate — Immediately post-procedure (intraoperative). Successful stent deployment with residual stenosis \<30% after the procedure (via angiography).
30-Day Major Adverse Events (MAE) Rate — 30 days (±7 days) post-procedure. Composite of:
All-cause death； Stroke (ischemic or hemorrhagic, with neurological deficits lasting ≥24h)； Myocardial infarction (MI) (per standard diagnostic criteria).
Trial sites (1)
Facility
City
Region
Status
Beijing An Zhen Hospital of the Capital University of Medical Sciences
Beijing
China
Recruiting
More Shanghai Bluesail Boyuan Medical Technology Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.